Publications

7. Gregor J, Adir Y, Šterclová M,  Mogulkoc N, Kramer MR, Doubková M, et al. The impact of switching to a second antifibrotic in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study from the EMPIRE registry. Archivos de Bronconeumología 2024; 60(2): 80-87. 2 citations
8. Šterclová M, Doubková M, Sýkorová L, Bartoš V, Žurková M., Lošťáková V, et al. Adherence to the ISHLT Protocol for the Referral of Patients with Idiopathic Pulmonary Fibrosis to the Transplantation Center among of Czech Centers for Interstitial Lung Diseases. Pulmonary Medicine 2024; 5918042. 1 citation
9. Štefániková M, Doubková M, Ovesná P, Šterclová M, Lacina L, Žurková M, et al. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry. BMC Pulmonary Medicine 2023; 23(1): 154. 13 citations
10. Májek O, Gregor J, Mogulkoc N, Lewandowska K, Šterclová M, Müller V, et al. Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone. PLoS ONE 2022; 17(9): e0273854. 4 citations
11. Nagy T, Toth NM, Palmer E, Polivka L, Csoma B, Nagy A, et al. Clinical predictors of lung-function decline in systemic-sclerosis-associated interstitial lung disease patients with normal spirometry. Biomedicines 2022; 10(9): 2129. 11 citations
12. Jovanovic DM, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study. Respiratory Research 2022; 23(1): 135. 34 citations
13. Kolonics-Farkas A, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Differences in baseline characteristics and access to treatment of newly diagnosed patients With IPF in the EMPIRE countries. Frontiers in Medicine 2021; 8: 729203. 9 citations
14. Doubková M, Kriegová E, Littnerová S, Schneiderová P, Šterclová M, Bartoš V, et al. DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study. Therapeutic Advances in Respiratory Disease 2021; 15: 17534666211042529. 16 citations
15. Kolonics-Farkas A, Šterclová M, Moğulkoç N, Kus J, Hájková M, Müller V, Jovanovic D, Tekavec-Trkanjec J, Littnerová S, Hejduk K, Vašáková M. Anticoagulant use and bleeding risk in Central European patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy: real-world data from EMPIRE. Drug Safety 2020; 43(10): 971–980. 18 citations
16. Tran T, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, Kramer MR, Jovanović D, Tekavec-Trkanjec J, Studnicka M, Stoeva N, Hejduk K, Dušek L, Suissa S, Vašáková M. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research 2020; 21: 11. 51 citations
17. Barczi E, Starobinski L, Kolonics-Farkas A, Eszes N, Bohacs A, Vašáková M, et al. Long-term effects and adverse events of nintedanib therapy in idiopathic pulmonary fibrosis patients with functionally advanced disease. Advances in Therapy 2019; 36(5): 1221–1232. 15 citations
18. Žurková M, Eva Kriegová E, Kolek V, Lošťáková V, Šterclová M, Bartoš M, et al. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respiratory Research 2019; 20: 16. 92 citations
19. Doubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. The Clinical Respiratory Journal 2018; 12(4): 1526–1535. 59 citations

Presentations at international conferences

1. Lewandowska K, Sobiecka M, Mogulkoc N, et al. Changes in the quality of life over time in patients with idiopathic pulmonary fibrosis (IPF) enrolled in the European Multipartner Registry (EMPIRE). ERS International Congress 2026, 5–9/9/2026, Barcelona.
2. Kamm J, Studnicka M, Gregor J, et al. The clinical course of IPF revisited – pattern of survival, lung function decline and duration of symptoms. ERS International Congress 2026, 5–9/9/2026, Barcelona.
3. Tóth NM, Kramer MR, Šterclová M, et al. Challenges in access and referral for lung transplantation in IPF: Data from the EMPIRE registry. ERS International Congress 2026, 5–9/9/2026, Barcelona.
4. Kamm J, Studnicka M, Gregor J, et al. Duration of Symptoms, Overall Survival and Fvc and Dlco Decline in Idiopathic Pulmonary Fibrosis (IPF) – Results From the EMPIRE Registry. ATS International Conference 2026, 15–20/5/2026, Orlando.
5. Koziar Vašáková M, Gregor J, Mogulkoc N, et al. Modelling of Overall Survival of IPF Patients With Different Phenotypes Treated With Nintedanib. ATS International Conference 2025, 16–21/5/2025, San Francisco.
6. Lang D, Lamprecht B, Mogulkoc N, et al. Statin use and its implications on survival and disease progression in the European MultiPartner Idiopathic Pulmonary Fibrosis Registry (EMPIRE). ERS International Congress 2024, 7–11/9/2024, Vienna.
7. Koziar Vašáková M, Šterclová M, Moğulkoç N, Kramer M, Doubková M, Plačková M, et al. The impact of switching to a second antifibrotic therapy on outcomes in patients with IPF in the EMPIRE registry treated with pirfenidone or nintedanib. Lecture and e-poster at the ATS International Conference 2023, 19–24/5/2023, Washington DC.
8. Lang D, Lamprecht B, Mogulkoc N, Šterclová M, Lewandowska K, Kramer et al. Clinical Characteristics and Survival According to the Presence of Velcro Crackles in the European Multipartner IPF Registry (EMPIRE). Poster presentation at the ATS International Conference 2023, 19–24/5/2023, Washington DC.
9. Koziar Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Kramer M, et al. Long-term effect of nintedanib treatment of idiopathic pulmonary fibrosis in 11 countries of Europe and Asia . Poster presentation at the ERS International Congress 2022, 4–6/9/2022, Barcelona.
10. Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M., et al. Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Poster presentation at the ERS International Congress 2021, 5–8/9/2021, virtual conference.
11. Jovanović DM, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry. Poster presentation at the ERS International Congress 2020, 6–9/9/2020, virtual conference.
12. Jovanović DM, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry. Poster presentation at the ERS International Congress 2020, 6–9/9/2020, virtual conference.
13. Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, et al. Pirfenidone effectiveness in idiopathic pulmonary fibrosis with different radiologic patterns. Poster presentation at the American Thoracic Society 2020 International Conference, 15–20/5/2020, Philadelphia.
14. Vašáková M, Šterclová M, Moğulkoç N, Lewandowska K, Müller V, Hájková M, Jovanovic D, Tekavec-Trkanjec J, Kramer M, Studnicka M, Stoeva N, Littnerová S, Hejduk K, Dušek L. Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidon or nintedanib or their switch. Real world data from the EMPIRE registry.
    Poster presentation at the ERS International Congress 2019, 28/9–2/10 2019, Madrid
15. Moğulkoç N, Tas MN, Kabasakal Y, Bishop PW, Littnerová S, Hejduk K, Vašáková M. Differences between ANCA positive and negative lung fibrosis cases without vasculitis.
    Poster presentation at the ERS International Congress 2019, 28/9–2/10 2019, Madrid
16. Vašáková M. EMPIRE registry.
    Oral presentation at the 5^th Central & Eastern European IPF Platform Workshop, 1/4/2019, Geneva
17. Kolonics-Farkas AM, Šterclová M, Mogulkoc N, Kus J, Müller V, Hájková M, et al. Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE)
    Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris
18. Mogulkoc N, Šterclová M, Müller V, Kus J, Hájková M, Jovanović DM, et al. Does body mass index have prognostic significance for patients with idiopathic pulmonary fibrosis?
    Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris
19. Müller V, Šterclová M, Mogulkoc N, Kus J, Hájková M, Jovanović DM, et al. Differences in baseline characteristics of newly diagnosed IPF patients in the EMPIRE countries.
    Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris
20. Vašáková M, Šterclová M,, Mogulkoc N, Kus J, Müller V, Hájková M, et al. Real world idiopathic pulmonary fibrosis in the EMPIRE registry.
    Poster presentation at the ERS International Congress 2018, 15–19/9/2018, Paris
21. Vašáková M, Schneiderová P, Kolek V, Šterclová M, Lošťáková V, Žurková M, et al. Genetic background of idiopathic pulmonary fibrosis in the Czech Republic. American Journal of Respiratory and Critical Care Medicine 2018; 197: A5746.
    Poster presentation at the American Thoracic Society 2018 International Conference, 18–23/5/2018, San Diego
22. Müller V. Learnings from IPF Registries in CEE – Is the diagnosis rate low? literature vs EMPIRE registry. Where the patients get lost? Solutions.
    Oral presentation at the 4^th Central & Eastern European IPF Platform Workshop, 17/4/2018, Budapest
23. Vašáková M. Patients portrait and diagnostic approach in CEE.
    Oral presentation at the 4^th Central & Eastern European IPF Platform Workshop, 17/4/2018, Budapest
24. Vašáková M. Real world: nintedanib in IPF
    Oral presentation at the 4^th Central & Eastern European IPF Platform Workshop, 17/4/2018, Budapest
25. Jovanović DM, Mogulkoc N, Šterclová M, Zolnowska B, Bartoš V, Plačková M, et al. Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry. European Respiratory Journal 2017; 50 (Suppl 61): OA1953.
    Oral presentation at the ERS International Congress 2017, 9–13/9/2017, Milan
    Times cited: 1 (Web of Science)
26. Lewandowska KB, Kus J, Zolnowska B, Sobiecka M, Martusewicz-Boros M, Sliwinski P, et al. Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry. European Respiratory Journal 2017; 50 (Suppl. 61): PA855.
    Poster presentation at the ERS International Congress 2017, 9–13/9/2017, Milan
27. Müller V, Mogulkoc N, Šterclová M, Zolnowska B, Bartoš V, Plačková M, et al. Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? European Respiratory Journal 2017; 50 (Suppl. 61): PA3821.
    Poster presentation at the ERS International Congress 2017, 9–13/9/2017, Milan
28. Vašáková M, Mogulkoc N, Šterclová M, Zolnowska B, Bartoš V, Plačková M, et al. Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real-world results from the EMPIRE registry. European Respiratory Journal 2017; 50 (Suppl 61): PA4880.
    Poster presentation at the ERS International Congress 2017, 9–13/9/2017, Milan
29. Vašáková M. Pathogenesis of hypersensitivity pneumonitis (HP) – current concepts.
    Oral presentation at the ERS International Congress 2017, 9–13/9/2017, Milan
30. Vašáková M. What did we learn about IPF management in some CEE counties? First results of IPF registry EMPIRE.
    Oral presentation at the 3^rd Central & Eastern European IPF Platform Workshop, 24/3/2017, Krakow
31. Kuś J.Practical approach to differential diagnosis of IPF.
    Oral presentation at the 3^rd Central & Eastern European IPF Platform Workshop, 24/3/2017, Krakow
32. Beunders I, Šterclová M. Patient advocacy groups in CEE: CIPFAPANET.
    Oral presentation at the 3^rd Central & Eastern European IPF Platform Workshop, 24/3/2017, Krakow
33. Vašáková M, Šterclová M, Bartoš J, Doubková M, Plačková M, Žurková M, et al. Do typical and atypical HRCT patterns make difference in prognosis of patients with IPF? European Respiratory Journal 2016; 48 (Suppl 60): PA795.
    Poster presentation at the ERS International Congress 2016, 3–7/9/2016, London
34. Vašáková M, Šterclová M, Kus J, Bartoš J, Hájková M, Doubková M, et al. Does early diagnosis of idiopathic pulmonary fibrosis matter? Real-world’s data from the EMPIRE registry. European Respiratory Journal 2016; 48 (Suppl. 60): PA794.
    Poster presentation at the ERS International Congress 2016, 3–7/9/2016, London
35. Žurková M, Kolek V, Lošťáková V, Kriegová E, Šterclová M, Bartoš V, et al. The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry. European Respiratory Journal 2016; 48 (Suppl. 60): PA2087.
    Poster presentation at the ERS International Congress 2016, 3–7/9/2016, London
36. Vašáková M. Registry of idiopathic pulmonary fibrosis patients (PG course)
    Oral presentation at the ERS International Congress 2016, 3–7/9/2016, London
37. Vašáková M. Current approach to diagnosis – how multi-disciplinary team (MDT) works?
    Oral presentation at the 2^nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague
38. Kuś J. What has been changed in national recommendation and access to treatment (country presentation) – Poland?
    Oral presentation at the 2^nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague
39. Müller V. What has been changed in national recommendation and access to treatment (country presentation) – Hungary?
    Oral presentation at the 2^nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague
40. Šterclová M. How to get patients to the centers early? Educational programs.
    Oral presentation at the 2^nd Central & Eastern European IPF Platform Workshop, 11/3/2016, Prague
41. Vašáková M. IPF Registry.
    Oral presentation at the Inaugural Central & Eastern European IPF Platform Workshop, 13–14/3/2015, Vienna
42. Müller V, Hájková M. IPF in the CEE Countries.
    Oral presentation at the Inaugural Central & Eastern European IPF Platform Workshop, 13–14/3/2015, Vienna
43. Vašáková M. Esbriet in IPF patients.
    A lecture for AB in Krakow

Articles in national journals

1. Vašáková M. Idiopatická plicní fibróza: umíme ji vždy správně diagnostikovat a léčit? [Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?] Vnitřní lékařství 2017; 63(11): 796–801.
2. Doubková M, Uher M, Bartoš V, Šterclová M, Lacina L, Lošťáková V, et al. Prognostické faktory idiopatické plicní fibrózy (IPF) – analýza Českého registru IPF [Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry]. Časopis lékařů českých 2016; 155(4): 188–194.
3. Žurková M, Neumannová K, Loštáková V, Tichý T, Kriegová E, Kolek V. Význam plicní rehabilitace u nemocných s idiopatickou plicní fibrózou [Effect of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis]. Studia pneumologica et phthiseologica 2015; 75(6): 213–218 .

The above-mentioned publications were supported by Boehringer Ingelheim.